相关实验视频

Updated: Jul 11, 2025

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

化疗治疗引起的DNA甲基化模式的改变与对嗅觉通路的负面影响有关

Peh Joo Ho^1,2,3, Alexis Jiaying Khng¹, Benita Kiat-Tee Tan^4,5,6

¹Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), 60 Biopolis Street, Genome, Singapore, 138672, Republic of Singapore.

Breast cancer research : BCR

|November 7, 2023

概括

化疗改变了乳腺癌患者的DNA甲基化 (DNAm),影响了嗅觉. 这项研究揭示了与气味相关的抑制生物过程,这表明DNAm变化和治疗后的感觉改变之间存在联系.

科学领域:

表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
基因组学就是基因组学.
癌症生物学癌症生物学

背景情况:

细胞毒性化疗可以诱导乳腺癌患者的DNA甲基化 (DNAm) 变化.
了解这些表观遗传变化对于管理治疗副作用至关重要.

研究的目的:

在乳腺癌患者中研究与化疗相关的DNA甲基化变化.
确定受化疗诱导的DNAm.影响的生物过程和途径.

主要方法:

在化疗前后对125名乳腺癌患者使用Illumina MethylationEPIC阵列进行DNAm分析.
使用了线性回归模型和基因组丰富分析 (GSEA).
用血液和唾液样本对1273名受治疗和872名未受治疗患者的单独队列进行验证.

主要成果:

141种差异甲基化CpG和11种促进剂与化疗有显著的关联.
GSEA确定了与嗅觉相关的六种被抑制的生物过程 (GO:0007606,GO:0007608,GO:0009593,GO:0050906,GO:0050907,GO:0050911).
在验证队列中,KEGG通路嗅觉转导 (hsa04740) 也被显著抑制.

结论:

化疗显著影响乳腺癌患者的DNA甲基化模式.
抑制的嗅觉转导通路表明,化疗可能会改变嗅觉感知.
印制基因的丰富表明化学疗法诱导的感官变化的潜在机制.

关键词:

乳腺癌乳腺癌乳腺癌通过DNA甲基化.表观遗传修饰是一种表观遗传修饰.对治疗的反应反应.

更多相关视频

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

Author Spotlight: Assessing the Olfactory Effects of Airborne Pollutants — Buried Food and Social Odor Tests

Author Spotlight: Assessing the Olfactory Effects of Airborne Pollutants — Buried Food and Social Odor Tests

Published on: September 13, 2024

相关概念视频

Epigenetic Regulation

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...

Phase II Reactions: Methylation Reactions

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...